WO2016142950A1 - A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form - Google Patents

A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form Download PDF

Info

Publication number
WO2016142950A1
WO2016142950A1 PCT/IN2015/000332 IN2015000332W WO2016142950A1 WO 2016142950 A1 WO2016142950 A1 WO 2016142950A1 IN 2015000332 W IN2015000332 W IN 2015000332W WO 2016142950 A1 WO2016142950 A1 WO 2016142950A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
methyl
fluoro
pyran
tetrahydro
Prior art date
Application number
PCT/IN2015/000332
Other languages
French (fr)
Inventor
Vijay Trimbak KADAM
Saikrishna
Vikram Appasaheb DHERE
Harpreet Singh Minhas
Gurpreet Singh Minhas
Original Assignee
Harman Finochem Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harman Finochem Limited filed Critical Harman Finochem Limited
Publication of WO2016142950A1 publication Critical patent/WO2016142950A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/12—Radicals substituted by halogen atoms or nitro or nitroso radicals

Definitions

  • the present invention relates to anindustrially feasible process for preparation of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6- hydroxymethyl-tetrahydro-pyran-3 ,4,5 -triol.
  • (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol (Formula-I) is having an inhibitory activity against sodium dependent glucose transporter (SGLT), the transporter is responsible for reabsorbing the majority of glucose filtered by the kidney and is marketed under the trade name "Invokana".
  • (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol is also known as (l S)-l,5-anhydro-l-[3-[[5- (4-fluorophenyl)-2-thien l]methyl]-4-methylphenyl]-D-glucitol.
  • US 7,943,788 B2 discloses(2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2- ylmethyl]-4-methyl -phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol and its pharmaceutically acceptable salts and its preparation process as depicted in Scheme-I.
  • US'788 discloses the reaction of 2-(4-fluoro phenyl)-5-(5-iodo-2-methylbenzyl)- thiophene with 2,3,4,6-tetrakis-0-trimethylsilyl-D-glucono-l,5-lactone in presence of n- butyl lithium in hexane, tetrahydrofuran, toluene to obtain lactol compound which further reacts with methane sulfonic acid in methanol to give methyl ether compound whichreacts with triisopropylsilane and boron trifluoridediethylether complex in presence of dichloromethane to get residue of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol which further purified
  • WO 2009035969 Al and WO 2010043682 A2 disclose novel process for preparing(2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol.
  • WO'969 describes reaction of 2-(4-fluorophenyl)-5-(5-iodo-2- methylbenzyl)thiophene with 2,3,4,6-tetra-o-trimethylsilyl-P-D-glucolacone in presence of tetrahydrofuran,(trimethylsilyl) methyllithium in hexane to get an intermediate as a thick oil which further reacts with triethylsilane, boron trifluoridediethyletherate in presence of dichloromethane to get 1 -( ⁇ -D-glucopyranosyl)- 4-methyl-3-(5-(4-flurophenyl)-2-thienylmethyl) benzene as a green foam which further reacts with acetic anhydride in presence of 4-methyl morpholine, DAMP and tetrahydrofuran to get acetylprotected compound which further undergoes for deprotection in presence of lithium hydroxide as a
  • US 7,943,582 B2 describes a novel crystal form of 1 -(P-D-glucopyranosyl)-4-methyl- 3-[5-(4-fluorophenyl)-2-thienylmethyl]benzenehemihydrates,methods for its preparation and isolation, as well as pharmaceutical compositions.
  • US 8,772,512 B2 describes a crystallization procedure to obtain l-(P-D-glucopyranosyl)- 4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene hemihydrate crystals.
  • O 2013064909 A2 provides amorphous forms and the crystalline complexes of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol which are designated as Forms CS1, CS2, CS3, CS4 and CS5.
  • US 20080146515 AI discloses a crystalline hemihydrate form of (2S,3R,4R,5S,6R)- 2- ⁇ 3 - [5 - [4-Fluoro-phenyl)-thiophen-2-ylmethyl] -4-methyl -phenyl ⁇ -6-hydroxymethyl- tetrahydro-pyran-3,4,5-triolas well asa process for the preparation of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6-hydroxymethyl- tetrahydro-pyran-3 ,4,5 -triolhemihydrates.
  • the present invention provides the process for preparation of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5- [4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol(Formula-I)and its stable amorphous hemihydrate form.
  • the present invention describes the silylation process for preparing 3,4,5- Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one from 3,4,5- Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-onewhich comprises;
  • the present invention discloses the process for preparing 2-R 1 -2- ⁇ 3-[5- (4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol from 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl- tetrahydro-pyran-2-one which comprises;
  • the present invention describes process for preparing (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol by reduction of 2-R 1 -2- ⁇ 3-[5-(4-fluoro- phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6- hydroxymethyl-tetrahydro-pyran- 3,4,5-triol which comprises;
  • the instant invention provides process for preparing stable amorphous hemihydrate of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2- ylmethyl]-4-methyl -phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol from (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol which comprises;
  • the present invention describes the preparation of L-proline complex of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol from (2S,3R,4R,5S,6R)-2- ⁇ 3-[5- [4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol which comprises;
  • the present invention describes the process for preparing amorphous hemihydrate of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2- ylmethyl]-4-methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol from L- proline complex of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol which comprises;
  • the present process gives a- Isomer in the range of 1-1.8 %., which is removed during purification; further, the Des-bromoimpuirity (2-(5-2-methyl-benzyl)-5-(4-fluoro- phenyl)-thiophene) formation is restricted to 10-13 %during purification. After adding Methanesulphonic acid/alcohol the reaction is kept only for 5 hrs. Further work up disclosed in present invention is advantageous over the teachings of prior art as the purification process does not involve column chromatography or any costly technique. The purification process simply carried out with solvents which is commercially feasible.
  • the instant invention provides an efficient, advantageous and economical process for preparing (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol(FormuIa-I)and its stable amorphous hemihydrate form.
  • the present invention describes the silylation process for preparing 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one from 3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-onewhich comprises;
  • solvent refers to polar aprotic solvents selected from the group consisting of tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide.
  • organic base is selected from the group consisting of triethylamine, diisopropyl ethylamine, N-methyl morpholine& N-methyl pyrrolidine.
  • the reaction is carried out at -5 to 0°C.
  • the instant invention discloses aprocess for preparing 2-R I -2- ⁇ 3- [5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6- hydroxymethyl- tetrahydro-pyran-3 ,4,5-triol from 3 ,4,5-Tris-trimethylsilanyloxy-6- trimethylsilanyloxymethyl-tetrahydro-pyran-2-one which comprises;
  • the polar aprotic solvent is selected from the group consisting of :etrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide.
  • the non-polar solvent is selected from the group consisting ofToluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether, Dichloromethane.
  • reaction temperature is -70 to -80°C.
  • organolithium reagent refers to alkyllithium reagents selected from the group consisting of n-butyl lithium, methyl lithium, t-butyl lithium.
  • alkyl sulfonic acid refers to methane sulfonic acid.
  • the unsaturated aliphatic alcohol is selected from the group consisting of allyl alcohol, propargyl alcohol, 3,7-dimethylocta-2,6-dien-l-ol.
  • the present process gives a- Isomer in the range of 1-1.8 %., which is removed during purification, Des-bromoimpuirity (2-(5-2-methyl-benzyl)-5-(4-fluoro-phenyl)-thiophene) formation is restricted to 10-13 %during purification.
  • R l is allyl or prop-2ynyl.
  • the invention encompasses the compound 2-Rl-2- ⁇ 3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl ⁇ -6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol of formula V.
  • R' is allyl, prop-2ynyl,.
  • the invention encompasses the novel intermediate compounds of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol, viz.,
  • the novel intermediate is having better leaving groups- allyl, propargyl as compare to hydroxyl, alkyl which increases reaction rate and gives higher yield with reducedreaction time.
  • the instant invention discloses process for preparing des-bromo (2-(4-fluoro-phenyl)-5-(2-methyl-benzyl)-thiophene) impurities which comprises;
  • the alkyllithium is selected from the group consisting of n-butyl lithium, methyl lithium, t-butyl lithium.
  • the polar aprotic solvent is selected from the group consisting of tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide.
  • the non-polar solvent is selected from the group consisting ofToluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether, Dichloromethane. According to above process the reaction temperature is -70 to -80°C.
  • the main object is achieved by removing the des-bromo impurity the p during purification of 2-Rl-2- ⁇ 3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ - 6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol, without invoving any special techniques., that makes the process less cumbersome and cost-effective.
  • the present invention describes process for preparing (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol by reduction of 2-R 1 -2- ⁇ 3-[5-(4-fluoro- phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6- hydroxymethyl-tetrahydro-pyran- 3,4,5-triol which comprises;
  • organosilane refers to alkylsilane or olyalkylsilanewhichis selected from the group consisting of trimethylsilane, iethylsilane, tetramethylsilane, dimethylsilane.
  • the non-polar solvent is selected from le group consisting of Dichloromethane, Toluene, Hexane, 1,4-Dioxane, Chloroform, •iethyl ether and the polar aprotic solvent is selected from the group consisting of ;etonitrile, tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, dimethyl ilfoxide.
  • the acid for the above said process is selected from the group consisting of orontrifloride in diethylether, trifluoroacetic acid, methanesulfonic acid,
  • R J is allyl or prop-2ynyl.
  • the instant invention provides process for preparing stable norphous hemihydrate of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2- lmethyl]-4-methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol from (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylrnethyl]-4-methyl-phenyl ⁇ -6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol which comprises;
  • the non-polar solvent for said process is selected from the group consisting of n-Heptane, Dichloromethane, Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether.
  • the ambient temperature is 25-30°C.
  • the main object of the present invention process is to get stable amorphous hemihydrate of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen- 2-ylmethyl]-4-methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol without using spray drier technique which makes the process simple, cost- effective and time saving.
  • the present invention describes the preparation of L-proline complex/cocrystal of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]- 4-methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol from (2S,3R,4R,5S,6R)- 2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6-hydroxymethyl- tetrahydro-pyran-3,4,5-triol which comprises;
  • the polar aprotic solvent for above said process is selected from the group consisting of ethyl acetate, acetone, acetonitrile, tetrahydrofuran, dimethylformamide, dimethyl sulfoxide and the non-polar solvent is selected from the group consisting of n-Heptane, Dichloromethane, Toluene, Hexane, 1 ,4-Dioxane, Chloroform, Diethyl ether.
  • the temperature for the above said process is 60-65°C.
  • the present invention describes the process for preparing amorphous hemihydrate of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2- ylmethyl]-4-methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol from L- proline complex of (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol which comprises;
  • Example-2 Preparation of 2-Al-yloxy-2- ⁇ 3-[5-(4-fluoro-phenyl)-thiophen-2- yImethyl]-4-methyI-phenyl ⁇ -6- hydroxymethyI-tetrahydro-pyran-3,4,5-triol
  • Aromatic C C stretching: 1510 , 1548 , 1603 , 1703 cm "1
  • reaction mass is quenched with Methane sulphonic acid and propargyl alcohol mixture at -70 to -80°C. Temperature was raised to ambient temperature and stirred over night. Reaction mass was quenched with 30 cc sat.sodiumbicarbonate solution to bring the pH neutral to alkaline. Reaction mass stirred for 30.0 min;layers separated and aqueous layer was extracted with 10 cc of Toluene.
  • Aromatic C C stretching: 1510 , 1548 , 1603 , 1703 cm "1
  • Example-4 Preparation of 2- ⁇ 3-[5-(4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
  • Example 8 Preparation of L-Proline - (2S,3R,4R,5S,6R)-2- ⁇ 3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl ⁇ -6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol co crystal

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention discloses the process for preparation of (2S,3R,4R,5S,6R)-2-{3-[5- [4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol and its stable amorphous hemihydrate form.

Description

"A novel process for preparing (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyI-phenyl}-6-hydroxymethyI-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form"
FIELD OF INVENTION:
The present invention relates to anindustrially feasible process for preparation of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3 ,4,5 -triol.
BACKGROUND OF INVENTION:
(2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol (Formula-I) is having an inhibitory activity against sodium dependent glucose transporter (SGLT), the transporter is responsible for reabsorbing the majority of glucose filtered by the kidney and is marketed under the trade name "Invokana".
(2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol is also known as (l S)-l,5-anhydro-l-[3-[[5- (4-fluorophenyl)-2-thien l]methyl]-4-methylphenyl]-D-glucitol.
Figure imgf000002_0001
Formula-I
(2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triolis first disclosed in US8222219, for the treatment of diabetes and related disorders.
US 7,943,788 B2 discloses(2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2- ylmethyl]-4-methyl -phenyl } -6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol and its pharmaceutically acceptable salts and its preparation process as depicted in Scheme-I.
Figure imgf000003_0001
CVl!I)
Scheme-1
US'788 discloses the reaction of 2-(4-fluoro phenyl)-5-(5-iodo-2-methylbenzyl)- thiophene with 2,3,4,6-tetrakis-0-trimethylsilyl-D-glucono-l,5-lactone in presence of n- butyl lithium in hexane, tetrahydrofuran, toluene to obtain lactol compound which further reacts with methane sulfonic acid in methanol to give methyl ether compound whichreacts with triisopropylsilane and boron trifluoridediethylether complex in presence of dichloromethane to get residue of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol which further purified with silica gel chromatograph to get pure (2S,3R,4R,5S,6R)-2-{3- [5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl- tetrahydro-pyran-3,4,5-triol.
WO 2009035969 Al and WO 2010043682 A2 disclose novel process for preparing(2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol. WO'969 describes reaction of 2-(4-fluorophenyl)-5-(5-iodo-2- methylbenzyl)thiophene with 2,3,4,6-tetra-o-trimethylsilyl-P-D-glucolacone in presence of tetrahydrofuran,(trimethylsilyl) methyllithium in hexane to get an intermediate as a thick oil which further reacts with triethylsilane, boron trifluoridediethyletherate in presence of dichloromethane to get 1 -(β-D-glucopyranosyl)- 4-methyl-3-(5-(4-flurophenyl)-2-thienylmethyl) benzene as a green foam which further reacts with acetic anhydride in presence of 4-methyl morpholine, DAMP and tetrahydrofuran to get acetylprotected compound which further undergoes for deprotection in presence of lithium hydroxide as a brittle foam which is further crystallized using ethyl acetate, water and n-heptane to get off white crystalline solid.
Prior artprocess (US'788) describe purification method by using silica gel columnchromatographywhich is major drawback of the said process. Final compound is purified by chloroformmethanol (19: 1) which is not industrially applicable. More over column chromatography is very tedious, time consuming arid industrially not viable process.When practically the said methodfollowed a-Isomerof the final product is formed in the range of 5-8% along with Des-bromo impurity formed in the range of 18- 20 %, which increases after addition of n-butyllithium and kept for overnight reaction. Moreoverlactone ring cleavage is observed in the range of 3-4% after addition ofMethanesulphonic Acid/Methanol and maintained overnight for reaction completion, the removal of which is difficult from the final product and hence results in lower yield, lower purity. Moreover, the reaction is lengthy and the separation of the final product from the reaction are also time consuming makes the process cumbersome and uneconomical. Prior art process (WO'969) results an intermediate 2-hydroxy-2-{3-[5-(4- fluoro-phenyl)-thiophen-2-ylmethyl] -4-methyl-phenyl } -6- hydroxymethyl-tetrahydro- pyran-3,4,5-triolas an oil, form which is difficult to pure and handle for next step. Moreover, WO'969 describes multiple process steps to get pure crystalline compound which makes the process lengthy, tedious and uneconomical.
US 7,943,582 B2 describesa novel crystal form of 1 -(P-D-glucopyranosyl)-4-methyl- 3-[5-(4-fluorophenyl)-2-thienylmethyl]benzenehemihydrates,methods for its preparation and isolation, as well as pharmaceutical compositions. US 8,772,512 B2 describes a crystallization procedure to obtain l-(P-D-glucopyranosyl)- 4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene hemihydrate crystals. O 2013064909 A2 provides amorphous forms and the crystalline complexes of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol which are designated as Forms CS1, CS2, CS3, CS4 and CS5.
US 20080146515 AI discloses a crystalline hemihydrate form of (2S,3R,4R,5S,6R)- 2- { 3 - [5 - [4-Fluoro-phenyl)-thiophen-2-ylmethyl] -4-methyl -phenyl } -6-hydroxymethyl- tetrahydro-pyran-3,4,5-triolas well asa process for the preparation of (2S,3R,4R,5S,6R)-2- {3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl- tetrahydro-pyran-3 ,4,5 -triolhemihydrates.
In the light of the above drawbacks, there is a need in the art to provide robust, safe and commercially viable process for preparing (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol.
Accordingly, it is an objective of the present invention to provide a commercially viable process for the preparation of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2- ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol, prepared via novel intermediates which gives higher yield and purity and facilitates easy recovery of final compound. The purification process does not involve column chromatography or any costly technique/equipment, however, carried out with solvents which is commercially feasible, that makes the present invention cost-effective over the teachings of prior art.
SUMMARY OF THE INVENTION:
The present invention provides the process for preparation of (2S,3R,4R,5S,6R)-2-{3-[5- [4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol(Formula-I)and its stable amorphous hemihydrate form.
Figure imgf000006_0001
Formula-I
In one aspect, the present invention describes the silylation process for preparing 3,4,5- Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one from 3,4,5- Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-onewhich comprises;
(a) Reacting 3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-one with trimethylsilyl chloride in presence of solvent and organic base at ambient temperature;
(b) Maintaining pH 7-8 by adding sat. sodium bicarbonate;
(c) Separating organic layer and distilled and
(d) Isolating 3 ,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro- pyran-2-one.
In another aspect, the present invention discloses the process for preparing 2-R1-2-{3-[5- (4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol from 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl- tetrahydro-pyran-2-one which comprises;
(a) Reacting 2-(5-Bromo-2-methyl-benzyl)-5-(4-fluoro-phenyl)-thiophene with 3,4,5- Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one in presence of mixture of polar aprotic solvent and non-polar solvent, organolithium reagent, alkyl sulfonic acid, monohydric or unsaturated aliphatic alcohol;
(b) Bringing pH neutral to alkaline;
(c) Separating organic layer and
(d) Isolating 2-R1-2- {3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl} - 6- hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol.
In one another embodiment the present invention describes process for preparing (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol by reduction of 2-R1-2-{3-[5-(4-fluoro- phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran- 3,4,5-triol which comprises;
(a) Reacting 2-R'-2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol with organosilane in presence of acid, mixture of non-polar solvent and polar aprotic solvent under argon atmosphere;
(b) Quenching with sat. sodium bicarbonate solution;
(c) Separating layers; and
(d) Isolating (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]- 4-methyl -phenyl } -6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol.
In one another embodiment the instant invention provides process for preparing stable amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2- ylmethyl]-4-methyl -phenyl }-6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol from (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol which comprises;
(a) Stirring (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol with non-polar solvent at ambient temperature and
(b) Isolating stable amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro- phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol.
In another embodiment the present invention describes the preparation of L-proline complex of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl}-6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol from (2S,3R,4R,5S,6R)-2-{3-[5- [4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol which comprises;
(a) Reacting (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol with proline in presence of polar aprotic solvent under argon atmosphere;
(b) Adding non-polar solvent and (c) Isolating L-proline complex of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol.
In another embodiment the present invention describes the process for preparing amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2- ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol from L- proline complex of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol which comprises;
(a) Stirring (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl -phenyl }-6-hydroxymethyl-tetrahydro-pyran-3, 4, 5-triol in presence of ethyl acetate;
(b) Adding sat. sodium bicarbonate solution;
(c) Adding n-Heptane and
(d) Isolating stable amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4- Fluoro-phenyl)-thiophen-2-ylmethyl] -4-methyl -phenyl } -6-hydroxymethyl- tetrahydro-pyran-3 ,4,5 -triol.
The present process gives a- Isomer in the range of 1-1.8 %., which is removed during purification; further, the Des-bromoimpuirity (2-(5-2-methyl-benzyl)-5-(4-fluoro- phenyl)-thiophene) formation is restricted to 10-13 %during purification. After adding Methanesulphonic acid/alcohol the reaction is kept only for 5 hrs. Further work up disclosed in present invention is advantageous over the teachings of prior art as the purification process does not involve column chromatography or any costly technique. The purification process simply carried out with solvents which is commercially feasible. Thus the instant invention provides time saving, cost effective and commercially viable process for preparing (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]- 4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol. DETAILED DESCRIPTION OF THE INVENTION:
The instant invention provides an efficient, advantageous and economical process for preparing (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl} -6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol(FormuIa-I)and its stable amorphous hemihydrate form..
Figure imgf000009_0001
Formula-I
In one embodiment, the present invention describes the silylation process for preparing 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one from 3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-onewhich comprises;
(a) Reacting , 3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-one with trimethylsilyl chloride in presence of solvent and organic base at ambient temperature;
(b) Maintaining pH 7-8 by adding sat. sodium bicarbonate;
(c) Separating organic layer and distilled and
(d) Isolating 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro- pyran-2-one.
The process for preparing 3,4,5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl- tetrahydro-pyran-2-one depicted in the following reaction Scheme II.
Figure imgf000009_0002
Formula-ll Formula-
Scheme-II The term solvent refers to polar aprotic solvents selected from the group consisting of tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide. The organic base is selected from the group consisting of triethylamine, diisopropyl ethylamine, N-methyl morpholine& N-methyl pyrrolidine.
According to above process, the reaction is carried out at -5 to 0°C.
In another embodiment, the instant invention discloses aprocess for preparing 2-RI-2-{3- [5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl- tetrahydro-pyran-3 ,4,5-triol from 3 ,4,5-Tris-trimethylsilanyloxy-6- trimethylsilanyloxymethyl-tetrahydro-pyran-2-one which comprises;
(a) Reacting 2-(5-Bromo-2-methyl-benzyl)-5-(4-fluoro-phenyl)-thiophene with 3,4,5- Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one in presence of mixture of polar aprotic solvent and non-polar solvent, organolithium reagent, alkyl sulfonic acid, unsaturated aliphatic alcohol;
(b) Bringing pH neutral to alkaline;
(c) Separating organic layer and
(d) Isolating 2-R1-2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}- 6- hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol.
The reaction scheme for preparing 2-R'-2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]- 4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3 ,4,5 -triolis given in Scheme III.
Figure imgf000010_0001
Formula- Forrnula-IV Foirmula-V
Where R = allyl, prop-2-ynyi
Scheme-Ill
[n above said process, the polar aprotic solvent is selected from the group consisting of :etrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide. The non-polar solvent is selected from the group consisting ofToluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether, Dichloromethane.
According to above process the reaction temperature is -70 to -80°C.
The term organolithium reagent refers to alkyllithium reagents selected from the group consisting of n-butyl lithium, methyl lithium, t-butyl lithium. The term alkyl sulfonic acid refers to methane sulfonic acid. The unsaturated aliphatic alcohol is selected from the group consisting of allyl alcohol, propargyl alcohol, 3,7-dimethylocta-2,6-dien-l-ol.
The present process gives a- Isomer in the range of 1-1.8 %., which is removed during purification, Des-bromoimpuirity (2-(5-2-methyl-benzyl)-5-(4-fluoro-phenyl)-thiophene) formation is restricted to 10-13 %during purification.
In above process Rlis allyl or prop-2ynyl.
The main advantage of above said process is that the deprotection process undergoes insitu simultaneously. Therefore additional and multiple steps/ work up can be avoided which results in economical, time saving and safe process.Accordingly, the invention encompasses the compound 2-Rl-2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol of formula V.
Figure imgf000011_0001
Formda-V
Wherein, R'is allyl, prop-2ynyl,.
Therefore, the invention encompasses the novel intermediate compounds of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol, viz.,
a) 2- allyl -2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol; b) 2- prop-2ynyl -2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}- 6- hydroxymethyl-tetrafrydro-pyran-3,4,5-triol;
The novel intermediate is having better leaving groups- allyl, propargyl as compare to hydroxyl, alkyl which increases reaction rate and gives higher yield with reducedreaction time.
In another embodiment the instant invention discloses process for preparing des-bromo (2-(4-fluoro-phenyl)-5-(2-methyl-benzyl)-thiophene) impurities which comprises;
(a) Reacting 2-(5-bromo-2-methyl-benzyl)-5-(4-fluoro-phenyl)-thiophene with alkyllithiumin presence of mixture of polar aprotic solvent and non-polar solvent;
(b) Adding ammonium chloride solution and
(c) Isolating 2-(4-fluoro-phenyl)-5-(2-methyl-benzyl)-thiophene.
The alkyllithiumis selected from the group consisting of n-butyl lithium, methyl lithium, t-butyl lithium. The polar aprotic solvent is selected from the group consisting of tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide. The non-polar solvent is selected from the group consisting ofToluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether, Dichloromethane. According to above process the reaction temperature is -70 to -80°C.
The main object is achieved by removing the des-bromo impurity the p during purification of 2-Rl-2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}- 6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol, without invoving any special techniques., that makes the process less cumbersome and cost-effective.
In one another embodiment the present invention describes process for preparing (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol by reduction of 2-R1-2-{3-[5-(4-fluoro- phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran- 3,4,5-triol which comprises;
(a) Reacting 2-R1-2- { 3 -[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol with organosilane in presence of acid, mixture of non-polar solvent and polar aprotic solvent under argon atmosphere;
(b) Quenching the reaction mass with sat. sodium bicarbonate solution;
(c) Separating layers and
(d) Isolating (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]- 4-methyl-phenyl } -6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol.
he reaction scheme for said process is given in Scheme-IV.
Figure imgf000013_0001
Formula-V
Formula-I ire R.|= ally I, prop-2-ynyl
Scheme-IV
.ccording to above said process the term organosilane refers to alkylsilane or olyalkylsilanewhichis selected from the group consisting of trimethylsilane, iethylsilane, tetramethylsilane, dimethylsilane. The non-polar solvent is selected from le group consisting of Dichloromethane, Toluene, Hexane, 1,4-Dioxane, Chloroform, •iethyl ether and the polar aprotic solvent is selected from the group consisting of ;etonitrile, tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, dimethyl ilfoxide. The acid for the above said process is selected from the group consisting of orontrifloride in diethylether, trifluoroacetic acid, methanesulfonic acid,
he above reaction is carried out at -40 to 55 °C.
l above process RJis allyl or prop-2ynyl.
i one another embodiment the instant invention provides process for preparing stable norphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2- lmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol from (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylrnethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol which comprises;
(a) Stirring(2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl } -6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol with non-polar solvent at ambient temperature and
(b) Isolating stable amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro- phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol.
The non-polar solvent for said process is selected from the group consisting of n-Heptane, Dichloromethane, Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether. The ambient temperature is 25-30°C.
In prior art WO 2014195966 A2 (herein after WO'966) preparation of amorphous form of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethylj-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol by spray drying method is disclosed. In WO'966 JISL Mini spray drier LSD-48 is used to get stable amorphous form of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol which makes the process very tedious, expensive and time consuming. The main object of the present invention process is to get stable amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen- 2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol without using spray drier technique which makes the process simple, cost- effective and time saving.
In another embodiment the present invention describes the preparation of L-proline complex/cocrystal of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]- 4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol from (2S,3R,4R,5S,6R)- 2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl- tetrahydro-pyran-3,4,5-triol which comprises;
(a) Reacting (2S 3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol with L-proline in presence of polar aprotic solvent under argon atmosphere; (b) Adding non-polar solvent and
(c) Isolating L-proline complex of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol.
The reaction scheme for said process is given in Scheme-V.
Figure imgf000015_0001
Formula-I Formula-I(a)
Scheme-V
The polar aprotic solvent for above said process is selected from the group consisting of ethyl acetate, acetone, acetonitrile, tetrahydrofuran, dimethylformamide, dimethyl sulfoxide and the non-polar solvent is selected from the group consisting of n-Heptane, Dichloromethane, Toluene, Hexane, 1 ,4-Dioxane, Chloroform, Diethyl ether. The temperature for the above said process is 60-65°C.
In another embodiment the present invention describes the process for preparing amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2- ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol from L- proline complex of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl} -6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol which comprises;
(a) Stirring L-proline complex of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran- 3,4,5-triol in presence of ethyl acetate;
(b) Adding sat. sodium bicarbonate solution;
(c) Adding n-Heptane and
(d) Isolating stable amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4- Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl- tetrahydro-pyran-3 ,4,5-triol The following examples, which include preferred embodiments, will serve to illustrate the' practice of this invention, it being understood that the particulars shown are by way of example and for purpose of illustrative discussion of preferred embodiments of the invention.
Examples:
Example-l: Preparation of 3,4,5-Tris-trimethylsilanyloxy-6- trimethylsilanyloxymethyl-tetrahydro-pyran-2-one
To 750 cc of dry THF added 1.12 mole 3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro- pyran-2-one at ambient temperature and stirred for 20 min. To the reaction mass added 9.0 mole N-Methyl morpholine and stirred for another 30.0 min at ambient temperature. Reaction mass is cooled to -5 °Cto 0°Cand stirred for 30.0 min. Added 18.0 mole Trimethylsillyl chloride at the temperature of -5 °C to 0 °Cand stirred for 30.0 min. The temperaturewasraised to 25 °C to 30 °C and maintained for 18-20hrs. After reaction complies by GC, reaction mass was cooled to -5 deg to 0 deg. Added Sat.Sodium bicarbonate solution to obtain the pH 7-8and stirred for 1 hr at 0 °C. Added 500 cc toluene and stirred for lhr. Reaction mass was settled down for 30.0 min and layers separated. To the Aqueous layer added 250 cc of toluene and stirred for 30.0 min. Layers separated and both the organic layers were combined and back washed with sat.brine solution. Organic layer was distilled under reduced pressure at a temperature of about 40 - 48 deg°Candunloaded 91 to 93% of oily mass.
HPLC purity: 92-96%
Example-2: Preparation of 2-Al-yloxy-2-{3-[5-(4-fluoro-phenyl)-thiophen-2- yImethyl]-4-methyI-phenyl}-6- hydroxymethyI-tetrahydro-pyran-3,4,5-triol
To themixture of 10 ccTHF and 10 cc Toluene added 0.138 mole 2-(5-Bromo-2-methyl- benzyl)-5-(4-fluoro-phenyl)-thiopheneatambient temperature. The reaction mass was stirred for 15 min. Cooled to -70 to -80°C in dry ice /acetone bath and stirred for 15 min. Added a solution of 0.014 mole n-Butyl lithium (1.9M in hexanes) at -70 to -80°C. and stirred for lhr. Added solution of 3, 4, 5-Tris-trimethylsilanyloxy-6- trimethylsilanyloxymethyl-tetrahydro-pyran-2-one in 5 cc of Toluene at -70 to -80°C and stirred for 2 to 3hrs. After the compliance of the reaction,thereaction mass was quenched with Methane sulphonic acid and Allyl alcohol mixture at -70 to -80°C. Temperature was raised to ambient temperature and stirred over night. Reaction mass was quenched with
30 cc sat.sodiumbicarbonate solution to bring the pH neutral to alkaline. Reaction mass stirred for 30.0 min. Layers separated and aqueous was extracted with 10 cc of Toluene.
Organic layer was combined and washed with water 30cc and sat. brine solution 50 cc.
Organic layer was distilled under reduced pressure to recover the toluene. Solid compound thus obtainedwas dissolved in 50cc of toluene and quenched in n-Hexane to obtain 75-79% the titled compound as crystalline solid.
HPLC purity:88-94 %.
IR dataiAromatic C- F stretching: 832 cm"1
Lactones C - O stretching: 1045 - 1092 cm-1
Allylic C- O stretching: 1161 cm"1
Anomeric C-O stretching: 1231 cm"1
Aromatic C=C stretching: 1510 , 1548 , 1603 , 1703 cm"1
Alkane C - H stretching: 2892 , 2950 cm"1
Allylic C- H stretching: 2990 - 3120 cm"1
Aromatic C - H stretching: 3050 - 3090 cm"1
Lactones O - H stretching: 3240 - 3380 cm"1
Dip - Mass
(M+Na) 523.28 m/z
Figure imgf000017_0001
Example 3: Preparation of 2- prop-2ynyl -2-{3-[5-(4-fluoro-phenyl)-thiophen-2- ylmethyl] -4-methyl -phenyl } -6- hydroxymethyl-tetrahydro-pyran-3 ,4,5-triol
To themixture of 10 ccTHF and 10 cc Toluene added 0.138 mole 2-(5-Bromo-2-methyl- benzyl)-5-(4-fluoro-phenyl)-thiopheneatambient temperature. The reaction mass is stirred for 15 min. Cooled to -70 to -80°C in dry ice /acetone bath and stirred for 15 min. Added a solution of 0.014 mole n-Butyl lithium (1.9M in hexanes) at -70 to -80°C. and stirred for lhr. Added solution of 3, 4, 5-Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl- tetrahydro-pyran-2-one in 5 cc of Toluene at -70 to -80°C and stirred for 2 to 3hrs. After the compliance of the reaction, reaction mass is quenched with Methane sulphonic acid and propargyl alcohol mixture at -70 to -80°C. Temperature was raised to ambient temperature and stirred over night. Reaction mass was quenched with 30 cc sat.sodiumbicarbonate solution to bring the pH neutral to alkaline. Reaction mass stirred for 30.0 min;layers separated and aqueous layer was extracted with 10 cc of Toluene.
Organic layer was combined and washed with water 30cc and sat. brine solution 50 cc.
Organic layer was distilled under reduced pressure to recover the toluene. Solid compound thus obtained was dissolved in 50cc of toluene and quenched in n-Hexane to obtain 75-79% of the titled compound as crystalline solid.
HPLC purity: 88-94 %.
IR dataiAromatic C- F stretching: 878 cm"1
Lactones C - O stretching: 1045 - 1092 cm'1
Propargylic C- O stretching: 1 161 cm"1
Anomeric C-0 stretching: 1231 cm"1
Aromatic C=C stretching: 1510 , 1548 , 1603 , 1703 cm"1
Propargylic C- H stretching: 2125 cm"1
Alkane C - H stretching: 2892 , 2950 cm"1
Aromatic C - H stretching: 3050 - 3090 cm"1
Lactones O - H stretching: 3240 - 3380 cm"1
Dip-Mass ;
(M+Na) 521.31 m/z
(M+K) 537.31 m/z
Example-4: Preparation of 2-{3-[5-(4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
To themixture of 20 cc(l :l MDC + ACN) added 0.11 mole 2-Allyloxy-2-{3-[5-(4-fluoro- phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-3,4,5-tris-trimethylsilanyloxy-6- trimethylsilanyloxymethyl-tetrahydro-pyran under argon atmosphere. Stirred the reaction mass for 30.0 min.Cooled the reaction mass to -40 to -55°C in a dry ice/acetone bath under argon atmosphere. Charged 3 mole Triethylsilane at -40 to -55°Candstirred the reaction mass for 30.0 min at -50 to -55°C. Slowly addedBorontrifloride in diethyl ether solution at -40 to -55°C and stirred the reaction mass for 2 hrs. Quenched the reaction mass with 50 cc sat. sodium bicarbonate solution at -40 to -55°C . andStirred the reaction mass for 30.0 min. Slowly raised the temperature to 25 to 30°C. Settled downthe reaction mass and separated the layers, extracted the aqueous layer with 100 cc of MDC. Combined the organic layer and washed with 500 cc water. Washed the organic layer with 500 cc of sat.Brmesolution.Distilled out the MDC under reduced pressure below 40°C.to get 85-87% titled compound as light yellow solid.
HPLC purity: 90-95%
Example5: Preparation of 2-{3-[5-(4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
To themixture of 20 cc(l : l MDC + ACN) added 0.1 1 mole 2- prop-2ynyl -2-{3-[5-(4- fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro- pyran-3,4,5-triolunder argon atmosphere. Stirred the reaction mass for 30.0 min.Cooled the reaction mass to -40 to -55°C in a dry ice/acetone bath under argon atmosphere. Charged 3 mole Triethylsilane at -40 to -55°Candstirred the reaction mass for 30.0 min at -50 to -55°C. Slowly addedBorontrifloride in diethyl ether solution at -40 to -55°C and stirred the reaction mass for 2 hrs. Quenched the reaction mass with 50 cc sat. sodium bicarbonate solution at -40 to -55°C . andstirred the reaction mass for 30.0 min. Slowly raised the temperature to 25 to 30°C. Settled downthe reaction mass and separated the layers, extracted the aqueous layer with 100 cc of MDC. Combined the organic layers and washed with 500 cc water. Washed the organic layer with 500 cc of sat.Brmesolution.Distilled out the MDC under reduced pressure below 40°C.to get85- 87% titled compound aslight yellow solid.
HPLC purity: 90-95%
Example 6:
Preparation of amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol To the solid obtained from example 4 charged 500cc of n-heptane and stirred for ½hrs at ambient temperature. Heated the reaction mass to 55-60°C and stirred it for 2-3 hrs.; cooled to room temperature and maintained for 4-5 hrs. Filtered the solid and washed the cake with 100 cc n-heptane. Dried at 40-45°C to get amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyll-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3 ,4,5 -triol . Example 7:
Preparation of amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol To the solid obtained from example 5 charged 500cc of n-heptane and stirred for ½ hrs at ambient temperature. Heated the reaction mass to 55-60°C and stirred it for 2-3 hrs., cooled to room temperature and maintained for 4-5 hrs. Filtered the solid and washed the cake with 100 cc n-heptane. Dried at 40-45 °C to get amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol.
Example 8: Preparation of L-Proline - (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol co crystal
To the 10 cc of Ethyl acetate charged 1.0 mole (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro- phenyl)-thiophen-2-ylmethyl] -4-methyl -phenyl } -6-hydroxymethyl-tetrahydro-pyran- 3,4,5-triolunder argon atmosphere at ambient temperature andstirred for 30.0 min to get clear solution. Slowly heated the reaction mass to 60 - 65°C andstirredfor 1 hr. Slowly addedL-proline at 60 - 65°C andmaintained for 1 hr. Slowly added 15 cc n-Heptane to the reaction mass at 60 - 65°C andstirred the mass for 2.5 hrs. Cooled the mass to ambient temperature for 3-4 hrs and maintained for 5 hrs.Filteredthe mass under argon atmosphere.Washed the cake with 10 cc n-Heptane.Dried the cake at 50-55°C under reduced pressure to get 85-93% titled compound.
HPLC purity: 98-99.8%
Example 9: Preparation of L-Proline - (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol co crystal
To the 10 cc of acetonecharged 1.0 mole (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl] -4-methyl-phenyl } -6-hydroxymethyl-tetrahydro-pyran-3 ,4,5 - triolunder argon atmosphere at ambient temperature andstirred for 30.0 min to get clear solution. Slowly heated the reaction mass to 60 - 65 °C andstirredfor 1 hr. Slowly addedL- proline at 60 - 65°C andmaintained for 1 hr. Slowly added 15 cc n-Heptane to the reaction mass at 60 - 65°C andstirred the mass for 2.5 hrs. Cooled the mass to ambient temperature for 3-4 hrs and maintained for 5 hrs.Filteredthe mass under argon atmosphere. Washed the cake with 10 cc n-Heptane.Dried the cake at 50-55°C under reduced pressureto get 85-93% titled compound.
HPLC purity:98-99.8%
Example 10: Preparation of amorphous hemihydrate of (2S,3R»4R,5S,6R)-2-{3-[5-
[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyI- tetrahydro-pyran-3,4,5-triol
To the 15 cc ethyl acetate added(2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2- ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol at ambient temperatureandstirred for 30.0 min. Slowly added 5- 8 cc sat. sodium bicarbonate solution at ambient temperature and stirred for 1.5 hr to get the clear solution. Settleddownthe mass and separatedlayers. Extracted the aqueous layer with, 25 cc ethyl acetate. Combined the organic layers and washed the ethyl acetate layer with 50 cc sat. Sodium chloride solution.Distilled out ethyl acetate under reduced pressure at 40 - 45°C to get fluffy solid. Charged50 cc n-Heptane and stirred for 5 hrs to get 60-65% the title compound as Amorphous solid.
HPLC purity:99.8 %
Example 11: Preparation of 2-(4-FIuoro-phenyl)-5-(2-methyI-benzyI)-thiophene (impurity)
To the mixture of 20 cc THF and 20 cc Toluene charged 0.25 mole 2-(5-Bromo-2- methyl-benzyl)-5-(4-fluoro-phenyl)-thiopheneand Cooled to - 78°C. Added n-Butyl lithium (1.9 M in hexane) and Stirred for 30 min at - 78°C. Slowly added 20 % Ammonium chloride solution to the reaction mass and raised the temperature from - 78°C to -50°C. slowlybrought the reaction mass to ambient temperature and stirred for 30 min. Settled and separated layers, extracted the aqueous layer with 50 cc toluene. Washed the organic layer with 500 cc brine solution. Distilled out the toluene and charged heptane and stirred for 2 to 3 hrs at ambient temperature. Filtered the product and dried at 45 - 50°C under reduced pressure to obtain 88 %titled product
Mass: (m+1) 283 m/z found 283.51
HPLC Purity : 97.5 %

Claims

We claim,
1. A process for preparing (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2- ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
(Formula-I) comprising
Figure imgf000022_0001
Formula-I
(a) Reacting 2-(5-Bromo-2-methyl-benzyl)-5-(4-fluoro-phenyl)-thiophene with 3,4,5- Tris-trimethylsilanyloxy-6-trimethylsilanyloxymethyl-tetrahydro-pyran-2-one in presence of mixture of polar aprotic solvent and non-polar solvent, organolithium reagent, alkyl sulfonic acid, unsaturated aliphatic alcohol;
(b) Bringing pH neutral to alkaline to isolate 2-R1-2-{3-[5-(4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran- 3,4,5-triol.
(c) Reacting 2-R1-2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol with organosilane in presence of acid, mixture of non-polar solvent and polar aprotic solvent under argon atmosphere and
(d) Quenching with sat. sodium bicarbonate solution to isolate(2S,3R,4R,5S,6R)-2- {3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol.
2. The process according to claim 1, whereinthepolar aprotic solvent is selected from the group consisting of acetonitrile, tetrahydrofuran, ethyl acetate, acetone, dimethylformamideanddimethylsulfoxide.
3. The process according to claim 1, wherein the non-polar solvent is selected from the group consisting ofDichloromethane, Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether,n-Heptane.
4. The process according to claim 1, wherein R1 is allyl, prop-2ynyl,.
5. The process according to claim 1, wherein the organolithium reagent is alkyllithium reagents selected from the group consisting of n-butyl lithium, methyl lithium, t-butyl lithium.
6. The process according to claim 1, whereinthealkyl sulfonic acid is methane sulfonic acid.
7. The process according to claim 1, whereinthe unsaturated aliphatic alcohol is selected from the group consisting of allyl alcohol, propargyl alcohol.
8. The process according to claim 1, whereintheacid is borontrifloride in diethylether, trifluoroacetic acid, methanesulfonic acid.
9. The process according to claim 1 , whereintheorganosilaneisalkylsilane or polyalkylsilane selected from the group consisting of trimethylsilane, triethylsilane, tetramethylsilane, dimethylsilane.
10. The process according to claim 1, wherein the reaction temperature for step (a) and (e) is -70 to -80°C and -40 to -55 °C respectively.
11. A process for preparing stable amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3- [5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl- tetrahydro-pyran-3,4,5-triol comprising
(a) Stirring (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl} -6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol with non-polar solvent at ambient temperature and
(b) Isolating stable amorphous hemihydrate of (2S,3R,4R,5S,6R)-2-{3-[5-[4- Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl- tetrahydro-pyran-3 ,4,5-triol
12. The process according to claim 11, where innon-polar solvent is n-heptane.
13. A process for preparing L-prolin complex of (2S,3R,4R,5S,6R)-2-{3-[5-[4- Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl- tetrahydro-pyran-3,4,5-triol comprising
(a) Reacting (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4- methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol with L-proline in presence of polar aprotic solvent under argon atmosphere;
(b) Adding non-polar solvent and
(c) Isolating L-proline complex of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol.
14. The process according to claim 13, whereinthepolar aprotic solvent is ethyl acetate or acetone and non-polar solvent is n-Heptane.
15. The process according to any of the preceding claims, wherein the purity of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol and L-proline complex of (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol is 99.8% and 98-99.8% respectively.
16. The compound, 2-Rl-2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol of formula V.
Figure imgf000024_0001
Forroiits-V
17. The compound according to claim 17 is selected from the group consisting of a) 2 - allyl -2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol; b) 2- prop-2ynyl -2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl- phenyl}-6- hydroxymethyl-tetrahydro-pyran-3,4,5-triol; and
18. A process for preparing des-bromo impurities (2-(4-fluoro-phenyl)-5-(2- methyl-benzyl)-thiophene) VI);
Figure imgf000025_0001
Formula- VI
(a) Reacting 2-(5-bromo-2-methyl-benzyl)-5-(4-fluoro-phenyl)-thiophene with alkyllithium in presence of mixture of polar aprotic solvent and non-polar solvent
(b) Adding ammonium chloride solution and
(c) Isolating 2-(4-fluoro-phenyl)-5-(2-methyl-benzyl)-thiophene
19. The process according to claim 19, wherein the alkyllithium reagents selected from the group consisting of n-butyl lithium, methyl lithium, t-butyl lithium.
20. The process according to claim 19, wherein the non-polar solvent is selected from the group consisting of Dichloromethane, Toluene, Hexane, 1,4-Dioxane, Chloroform, Diethyl ether ,n-Heptane.
21. The process according to claim 19, wherein the polar aprotic solvent is selected from the group consisting of acetonitrile, tetrahydrofuran, ethyl acetate, acetone, dimethylformamide and dimethylsulfoxide.
22. The process according to claim 19, wherein the reaction temperature is -70 to -
80°C.
PCT/IN2015/000332 2015-03-11 2015-08-24 A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form WO2016142950A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN795MU2015 2015-03-11
IN795/MUM/2015 2015-03-11

Publications (1)

Publication Number Publication Date
WO2016142950A1 true WO2016142950A1 (en) 2016-09-15

Family

ID=56880180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000332 WO2016142950A1 (en) 2015-03-11 2015-08-24 A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form

Country Status (1)

Country Link
WO (1) WO2016142950A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017064679A1 (en) * 2015-10-15 2017-04-20 Lupin Limited Process for the preparation of amorphous canagliflozin
CN110759941A (en) * 2019-11-29 2020-02-07 上海网义化工有限公司 Preparation method of D-gluconic acid-gamma-lactone and intermediate thereof
CN110903315A (en) * 2019-12-16 2020-03-24 上海网义化工有限公司 Preparation method of D-gluconic acid-gamma-lactone intermediate

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012326A1 (en) * 2003-08-01 2005-02-10 Tanabe Seiyaku Co., Ltd. Novel compounds having inhibitory activity against sodium-dependant transporter
US20080146515A1 (en) * 2006-12-04 2008-06-19 Mitsubishi Tanabe Pharma Corporation Crystalline form of 1-(beta-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
WO2011142478A1 (en) * 2010-05-11 2011-11-17 Mitsubishi Tanabe Pharma Corporation Canagliflozin containing tablets
WO2013064909A2 (en) * 2011-10-31 2013-05-10 Scinopharm Taiwan, Ltd. Crystalline and non-crystalline forms of sglt2 inhibitors
CN104151306A (en) * 2013-05-13 2014-11-19 北京新天宇科技开发有限公司 Canagliflozin new preparation method

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012326A1 (en) * 2003-08-01 2005-02-10 Tanabe Seiyaku Co., Ltd. Novel compounds having inhibitory activity against sodium-dependant transporter
US20080146515A1 (en) * 2006-12-04 2008-06-19 Mitsubishi Tanabe Pharma Corporation Crystalline form of 1-(beta-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
WO2011142478A1 (en) * 2010-05-11 2011-11-17 Mitsubishi Tanabe Pharma Corporation Canagliflozin containing tablets
WO2013064909A2 (en) * 2011-10-31 2013-05-10 Scinopharm Taiwan, Ltd. Crystalline and non-crystalline forms of sglt2 inhibitors
CN104151306A (en) * 2013-05-13 2014-11-19 北京新天宇科技开发有限公司 Canagliflozin new preparation method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUMIHIRO NOMURA ET AL.: "Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 17, 9 September 2010 (2010-09-09), pages 6355 - 6360, XP007915324 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017064679A1 (en) * 2015-10-15 2017-04-20 Lupin Limited Process for the preparation of amorphous canagliflozin
CN110759941A (en) * 2019-11-29 2020-02-07 上海网义化工有限公司 Preparation method of D-gluconic acid-gamma-lactone and intermediate thereof
CN110759941B (en) * 2019-11-29 2022-08-30 上海网义化工有限公司 Preparation method of D-gluconic acid-gamma-lactone and intermediate thereof
CN110903315A (en) * 2019-12-16 2020-03-24 上海网义化工有限公司 Preparation method of D-gluconic acid-gamma-lactone intermediate

Similar Documents

Publication Publication Date Title
WO2016147197A1 (en) A novel process for preparing (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2h-py ran-3,4,5-triol and its amorphous form
US8901322B2 (en) Crystalline forms of cabazitaxel and process for preparation thereof
EP3497090B1 (en) Novel processes for preparation of dapagliflozin or its solvates or co-crystals thereof
WO2016142950A1 (en) A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form
EP3634970B1 (en) Novel process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof
WO2009067960A2 (en) A method of manufacturing (3r,4s)-l-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3- hydroxypropyl)]-4-(4-hydroxyphenyl)-2-azetidinone and its intermediates
WO2010082128A1 (en) Process for the preparation of cis-nucleoside derivative
WO2007049295A2 (en) An improved one pot process for making key intermediate for gemcitabine hcl
WO2012038979A2 (en) A process for preparation of ertapenem
WO2013114382A1 (en) Crystalline darunavir
KR100877849B1 (en) Process for the efficient preparation of 3-hydroxytetrahydrofuran
KR20100028590A (en) A novel and highly stereoselective process for preparing gemcitabine and intermediates thereof
US20170183317A1 (en) Process for the preparation of a fluorolaction derivative
WO2017064679A1 (en) Process for the preparation of amorphous canagliflozin
CZ2000804A3 (en) Process for preparing protease inhibitor
WO2017060925A1 (en) Novel pipecolic acid co-crystals of dapagliflozin and process for the preparation thereof
KR100908363B1 (en) Stereoselective preparation method of tri-O-acetyl-5-deoxy-β-D-ribofuranose and separation method thereof
WO2009069011A1 (en) Process for the preparation of substituted 1,3-oxathiolanes
US7943780B2 (en) Process for the preparation of candesartan cilexetil
WO2017060924A1 (en) A novel pipecolic acid co-crystal of canagliflozin and process for the preparation thereof
EP2227478A1 (en) Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
Dondoni et al. Regio-and stereoselective conjugate addition of nitrogen nucleophiles to 2-alkenyl n-methylthiazolium iodides. synthesis of d-3-epi-daunosamine and some lincosamine analogues
JP7442663B2 (en) Intermediates useful for the synthesis of SGLT inhibitors and methods for producing SGLT inhibitors using the same
WO2018020506A1 (en) Process for the preparation of amorphous form of canagliflozin
KR20160098495A (en) Process for the preparation of empagliflozin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15884459

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15884459

Country of ref document: EP

Kind code of ref document: A1